SCHEMBL1704344

SCHEMBL1704344

CCN1CCN(Cc2ccc(NC(=O)c3ccc(-c4ccc5nc(NC(=O)C6CC6)sc5n4)cc3)cc2C(F)(F)F)CC1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.87
RET P07949 3/20 0.87
KIT P10721 2/20 0.87
PDGFRA P16234 2/20 0.87
KDR P35968 2/20 0.87
FLT3 P36888 2/20 0.87
TEK Q02763 2/20 0.87
STK10 O94804 1/20 0.87
BRAF P15056 1/20 0.87
FLT1 P17948 1/20 0.87
CDK11B P21127 1/20 0.87
CDK2 P24941 1/20 0.87
FLT4 P35916 1/20 0.87
CDK7 P50613 1/20 0.87
MAPK12 P53778 1/20 0.87
CDK3 Q00526 1/20 0.87
CDK5 Q00535 1/20 0.87
DDR1 Q08345 1/20 0.87
HIPK1 Q86Z02 1/20 0.87
IRAK4 Q9NWZ3 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29381604 0.93 KIT (1.00) ABL1RETKITPDGFRAKDR
SCHEMBL1696179 0.93 KIT (1.00) ABL1RETKITPDGFRAKDR
SCHEMBL31060759 0.93 KIT (1.00) ABL1RETKITPDGFRAKDR
SCHEMBL1705135 0.91 KIT (0.91) ABL1RETKITPDGFRAKDR
SCHEMBL1696223 0.90 STK10 (0.80) ABL1RETKITPDGFRAKDR
SCHEMBL1696375 0.90 ABL1 (0.80) ABL1RETKITPDGFRAKDR
SCHEMBL1696376 0.90 RET (0.79) ABL1RETKITPDGFRAKDR
SCHEMBL10158881 0.90 ABL1 (0.79) ABL1RETKITPDGFRAKDR
SCHEMBL1279527 0.89 ABL1 (0.69) ABL1RETKITPDGFRAKDR
SCHEMBL1279465 0.88 RET (0.86) ABL1RETKITPDGFRAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9505784-B2 Fused 2-aminothiazole compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-11-29 US disclosed
US-20150094315-A1 FUSED 2-AMINOTHIAZOLE COMPOUNDS DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-04-02 US disclosed
US-8765747-B2 Fused 2-aminothiazole compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2014-07-01 US disclosed
US-20120088766-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES DANA-FARBER CANCER INSTITUTE, INC. (US) 2012-04-12 US disclosed
WO-2010144909-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088766-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES OAT, OTC, DLD ABL1 1023/4885RET 2038/4885KIT 1570/4885
US-20150094315-A1 FUSED 2-AMINOTHIAZOLE COMPOUNDS GOT2, OAT, ABAT ABL1 318/4885RET 1896/4885KIT 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.